Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Jamal, Mohd Hafifi ^a   Ch'ng, Wei Choong ^a   Yusoff, Khatijah ^a   Shafee, Norazizah ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Breast cancer; Cisplatin resistant cells; Newcastle disease virus (NDV); Survivin

Indexed keywords

CISPLATIN; ONCOLYTIC PARAMYXOVIRUS; SURVIVIN;

ARTICLE; CANCER RESISTANCE; CELL STRAIN MCF 7; CELL STRUCTURE; CELL VIABILITY; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; NEWCASTLE DISEASE PARAMYXOVIRUS; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS; VIRUS REPLICATION; VIRUS STRAIN;

EID: 84864399917     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-35     Document Type: Article

References (35)

1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969, 222:385-386. 10.1038/222385a0, 5782119.
2. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999, 5:1007-1014.
3. Ott I, Gust R. Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med Chem 2007, 7:95-110. 10.2174/187152007779314071, 17266507.
4. Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011, 57:468-487. 10.1159/000334093, 22248721.
5. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985, 24:707-713. 10.1021/bi00324a025, 4039603.
6. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987, 34:155-166. 10.1016/0163-7258(87)90009-X, 3317449.
7. Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279. 10.1038/sj.onc.1206933, 14576837.
8. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010, 24:837-852. 10.1101/gad.1897010, 2854397, 20395368.
9. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3:917-921. 10.1038/nm0897-917, 9256286.
10. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31. 10.1016/j.critrevonc.2007.02.001, 17336087.
11. Nomura T, Yamasaki M, Nomura Y, Mimata H. Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol Rep 2005, 14:993-997.
12. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. Semin Cancer Biol 2004, 14:231-243. 10.1016/j.semcancer.2004.04.002, 15219616.
13. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 2005, 310:1499-1504. 10.1126/science.1120160, 16322459.
14. Nelson NJ. Scientific interest in Newcastle disease virus is reviving. J Natl Cancer Inst 1999, 91:1708-1710. 10.1093/jnci/91.20.1708, 10528013.
15. Cassel WA, Garrett RE. Newcastle Disease Virus as an Antineoplastic Agent. Cancer 1965, 18:863-868. 10.1002/1097-0142(196507)18:7<863::AID-CNCR2820180714>3.0.CO;2-V, 14308233.
16. Othman F, Ideris A, Motalleb G, Eshak Z, Rahmat A. Oncolytic effect of Newcastle Disease Virus AF2240 strain on the MCF-7 breast cancer cell line. Yakhteh Med J 2010, 12:17-24.
17. Ishida N, Taira H, Omata T, Mizumoto K, Hattori S, Iwasaki K, Kawakita M. Sequence of 2,617 nucleotides from the 3' end of Newcastle disease virus genome RNA and the predicted amino acid sequence of viral NP protein. Nucleic Acids Res 1986, 14:6551-6564. 10.1093/nar/14.16.6551, 311663, 3018673.
18. Zhu Y, Roshal M, Li F, Blackett J, Planelles V. Upregulation of survivin by HIV-1 Vpr. Apoptosis 2003, 8:71-79. 10.1023/A:1021653119934, 12510154.
19. Marusawa H, Matsuzawa S, Welsh K, Zou H, Armstrong R, Tamm I, Reed JC. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J 2003, 22:2729-2740. 10.1093/emboj/cdg263, 156760, 12773388.
20. Virrey JJ, Guan S, Li W, Schonthal AH, Chen TC, Hofman FM. Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. Am J Pathol 2008, 173:575-585. 10.2353/ajpath.2008.071079, 2475793, 18599610.
21. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008, 34:378-390. 10.1016/j.ctrv.2008.01.007, 18367336.
22. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005, 92:212-216. 2361850, 15611788.
23. Alabsi AM, Bakar SA, Ali R, Omar AR, Bejo MH, Ideris A, Ali AM. Effects of Newcastle Disease Virus Strains AF2240 and V4-UPM on Cytolysis and Apoptosis of Leukemia Cell Lines. Int J Mol Sci 2011, 12:8645-8660. 10.3390/ijms12128645, 3257094, 22272097.
24. Ali R, Alabsi AM, Ali AM, Ainideris, Omar AR, Yousoff K. Apoptosis induction and cytolytic effects of newcastle disease virus strain Af2240 on DBTRG.05 mg brain tumor cell line. Int J Cancer Res 2011, 7:25-35.
25. Lukyanova NY, Rusetskya NV, Tregubova NA, Chekhun VF. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 2009, 31:87-91.
26. Lazar I, Yaacov B, Shiloach T, Eliahoo E, Kadouri L, Lotem M, Perlman R, Zakay-Rones Z, Panet A, Ben-Yehuda D. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol 2010, 84:639-646. 10.1128/JVI.00401-09, 2798437, 19864394.
27. Meng S, Zhou Z, Chen F, Kong X, Liu H, Jiang K, Liu W, Hu M, Zhang X, Ding C, Wu Y. Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer Lett 2012, 317:56-64. 10.1016/j.canlet.2011.11.008, 22095029.
28. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 1983, 43:3998-4006.
29. Oliere S, Arguello M, Mesplede T, Tumilasci V, Nakhaei P, Stojdl D, Sonenberg N, Bell J, Hiscott J. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 2008, 82:5735-5749. 10.1128/JVI.02601-07, 2395143, 18417567.
30. Phoolcharoen W, Smith DR. Internalization of the dengue virus is cell cycle modulated in HepG2, but not Vero cells. J Med Virol 2004, 74:434-441. 10.1002/jmv.20195, 15368519.
31. Emmett SR, Dove B, Mahoney L, Wurm T, Hiscox JA. The cell cycle and virus infection. Methods Mol Biol 2005, 296:197-218.
32. Connell CM, Wheatley SP, McNeish IA. Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis. Cancer Res 2008, 68:7923-7931. 10.1158/0008-5472.CAN-08-0817, 18829549.
33. Pina-Oviedo S, Urbanska K, Radhakrishnan S, Sweet T, Reiss K, Khalili K, Del Valle L. Effects of JC virus infection on anti-apoptotic protein survivin in progressive multifocal leukoencephalopathy. Am J Pathol 2007, 170:1291-1304. 10.2353/ajpath.2007.060689, 1829462, 17392168.
34. Kumar B, Yadav A, Lang JC, Cipolla M, Schmitt AC, Arradaza N, Teknos TN, Kumar P. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther 2012, Epub ahead of print.
35. Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 2011, 85:6015-6023. 10.1128/JVI.01537-10, 3126310, 21471241.